Vaxcyte, Inc. (NASDAQ:PCVX) Receives $86.00 Average Target Price from Analysts

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have been assigned an average rating of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $86.00.

PCVX has been the subject of a number of recent analyst reports. Guggenheim reaffirmed a “buy” rating and issued a $116.00 price objective on shares of Vaxcyte in a research report on Monday, February 2nd. Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Needham & Company LLC upped their target price on Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. BTIG Research upped their target price on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, January 9th.

Insiders Place Their Bets

In other news, CAO Elvia Cowan sold 2,500 shares of the firm’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $58.59, for a total transaction of $146,475.00. Following the completion of the sale, the chief accounting officer directly owned 30,867 shares of the company’s stock, valued at $1,808,497.53. This trade represents a 7.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Jim Wassil sold 7,395 shares of Vaxcyte stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $58.88, for a total value of $435,417.60. Following the sale, the chief operating officer owned 166,818 shares in the company, valued at $9,822,243.84. The trade was a 4.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 11,787 shares of company stock valued at $687,031 in the last 90 days. Corporate insiders own 3.10% of the company’s stock.

Institutional Trading of Vaxcyte

Several hedge funds have recently added to or reduced their stakes in PCVX. Smartleaf Asset Management LLC grew its position in shares of Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in shares of Vaxcyte by 1,463.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after purchasing an additional 600 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Vaxcyte by 33.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares during the period. Allworth Financial LP lifted its stake in Vaxcyte by 148.9% in the third quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after purchasing an additional 731 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in Vaxcyte during the third quarter valued at $45,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Price Performance

NASDAQ PCVX opened at $58.38 on Wednesday. Vaxcyte has a 1 year low of $27.66 and a 1 year high of $65.00. The firm has a market cap of $8.40 billion, a price-to-earnings ratio of -10.39 and a beta of 1.38. The company has a fifty day moving average price of $56.54 and a 200-day moving average price of $48.55.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, February 24th. The company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.46) by ($0.34). During the same quarter in the prior year, the firm posted ($1.12) EPS. On average, research analysts anticipate that Vaxcyte will post -4.21 EPS for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.